{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:46:13Z","timestamp":1791233173402,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["COLABORACI\u00d3N RTC-2017-6379-1"],"award-info":[{"award-number":["COLABORACI\u00d3N RTC-2017-6379-1"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007136","name":"Secretar\u00eda de Estado de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["INVESTIGACI\u00d3N RTI2018-097625-B-I00"],"award-info":[{"award-number":["INVESTIGACI\u00d3N RTI2018-097625-B-I00"]}],"id":[{"id":"10.13039\/501100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,6,9]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Here, we compared BCG antitumoral efficacy with another live attenuated mycobacteria, MTBVAC, in an orthotopic mouse model of bladder cancer (BC). We aimed to identify both bacterial and host immunological factors to understand the antitumoral mechanisms behind effective bacterial immunotherapy for BC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that the expression of the BCG-absent proteins ESAT6\/CFP10 by MTBVAC was determinant in mediating bladder colonization by the bacteria, which correlated with augmented antitumoral efficacy. We further analyzed the mechanism of action of bacterial immunotherapy and found that it critically relied on the adaptive cytotoxic response. MTBVAC enhanced both tumor antigen-specific CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T-cell responses, in a process dependent on stimulation of type 1 conventional dendritic cells. Importantly, improved intravesical bacterial immunotherapy using MBTVAC induced eradication of fully established bladder tumors, both as a monotherapy and specially in combination with the immune checkpoint inhibitor antiprogrammed cell death ligand 1 (anti PD-L1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These results contribute to the understanding of the mechanisms behind successful bacterial immunotherapy against BC and characterize a novel therapeutic approach for BCG-unresponsive NMIBC cases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004325","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T21:30:11Z","timestamp":1656883811000},"page":"e004325","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04975178","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-201X","authenticated-orcid":false,"given":"Eduardo","family":"Moreo","sequence":"first","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Uranga","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pic\u00f3","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nardelli-Haefliger","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-7254","authenticated-orcid":false,"given":"Carlos","family":"del Fresno","sequence":"additional","affiliation":[{"name":"Hospital la Paz Institute for Health Research, IdiPAZ, Madrid, Spain"},{"name":"Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Murillo","sequence":"additional","affiliation":[{"name":"Grupo Zendal, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Puentes","sequence":"additional","affiliation":[{"name":"Grupo Zendal, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Grupo Zendal, Pontevedra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Vales-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Departamento de Inmunolog\u00eda y Oncolog\u00eda, CNB-CSIC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-0730","authenticated-orcid":false,"given":"Julian","family":"Pardo","sequence":"additional","affiliation":[{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"},{"name":"IIS Aragon\/CIBA, Universidad de Zaragoza, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-3984","authenticated-orcid":false,"given":"David","family":"Sancho","sequence":"additional","affiliation":[{"name":"Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-5478","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-9173","authenticated-orcid":false,"given":"Nacho","family":"Aguilo","sequence":"additional","affiliation":[{"name":"Departamento de Microbiolog\u00eda, Pediatr\u00eda, Radiolog\u00eda y Salud P\u00fablica, Universidad de Zaragoza\/IIS Aragon, Zaragoza, Spain"},{"name":"CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,3]]},"reference":[{"key":"2025100310091556000_10.7.e004325.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"2025100310091556000_10.7.e004325.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)58737-6"},{"key":"2025100310091556000_10.7.e004325.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11754.x"},{"key":"2025100310091556000_10.7.e004325.4","first-page":"157","article-title":"Managing the adverse events of intravesical Bacillus Calmette\u2013Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Reports Urol"},{"key":"2025100310091556000_10.7.e004325.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02678.x"},{"key":"2025100310091556000_10.7.e004325.6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"2025100310091556000_10.7.e004325.7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R"},{"key":"2025100310091556000_10.7.e004325.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.051"},{"key":"2025100310091556000_10.7.e004325.9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025100310091556000_10.7.e004325.10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-Attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100310091556000_10.7.e004325.11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trsl.2018.03.004","article-title":"Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer","volume":"197","author":"Alvarez-Arguedas","year":"2018","journal-title":"Transl Res"},{"key":"2025100310091556000_10.7.e004325.12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16085"},{"key":"2025100310091556000_10.7.e004325.13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0671"},{"key":"2025100310091556000_10.7.e004325.14","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Gu\u00e9rin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"2025100310091556000_10.7.e004325.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004421117"},{"key":"2025100310091556000_10.7.e004325.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003586"},{"key":"2025100310091556000_10.7.e004325.17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1346","article-title":"Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer","volume":"13","author":"Garris","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025100310091556000_10.7.e004325.18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01803"},{"key":"2025100310091556000_10.7.e004325.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.03237.x"},{"key":"2025100310091556000_10.7.e004325.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2009.06959.x"},{"key":"2025100310091556000_10.7.e004325.21","doi-asserted-by":"publisher","DOI":"10.1258\/002367705774286475"},{"key":"2025100310091556000_10.7.e004325.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051318"},{"key":"2025100310091556000_10.7.e004325.23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002051"},{"key":"2025100310091556000_10.7.e004325.24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025100310091556000_10.7.e004325.25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100310091556000_10.7.e004325.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2025100310091556000_10.7.e004325.27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"2025100310091556000_10.7.e004325.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.090"},{"key":"2025100310091556000_10.7.e004325.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.194"},{"key":"2025100310091556000_10.7.e004325.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"2025100310091556000_10.7.e004325.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.061"},{"key":"2025100310091556000_10.7.e004325.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15"},{"key":"2025100310091556000_10.7.e004325.33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"2025100310091556000_10.7.e004325.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.026"},{"key":"2025100310091556000_10.7.e004325.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1671-8"},{"key":"2025100310091556000_10.7.e004325.36","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025100310091556000_10.7.e004325.37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"2025100310091556000_10.7.e004325.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"2025100310091556000_10.7.e004325.39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025100310091556000_10.7.e004325.40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment","volume":"35","author":"Zhou","year":"2017","journal-title":"Urol Oncol"},{"key":"2025100310091556000_10.7.e004325.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"2025100310091556000_10.7.e004325.42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:09:26Z","timestamp":1759511366000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,3]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/jitc-2021-004325"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004325","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}